These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38453772)

  • 1. Shedding of Syncytiotrophoblast-Derived Extracellular Vesicles Is Increased in Placenta Previa and Accreta Spectrum.
    Tersigni C; Di Simone N; Lucchetti D; Colella F; Onori M; Perossini S; Vidiri A; Franco R; Sgambato A; Vatish M; Lanzone A; Scambia G; Cavaliere AF
    Reprod Sci; 2024 Jul; 31(7):2043-2048. PubMed ID: 38453772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customizing EV-CATCHER to Purify Placental Extracellular Vesicles from Maternal Plasma to Detect Placental Pathologies.
    Mitchell MI; Khalil M; Ben-Dov IZ; Alverez-Perez J; Illsley NP; Zamudio S; Al-Khan A; Loudig O
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-trimester ultrasound for antenatal diagnosis of placenta accreta spectrum in women with placenta previa: results from the ADoPAD study.
    Fratelli N; Prefumo F; Maggi C; Cavalli C; Sciarrone A; Garofalo A; Viora E; Vergani P; Ornaghi S; Betti M; Vaglio Tessitore I; Cavaliere AF; Buongiorno S; Vidiri A; Fabbri E; Ferrazzi E; Maggi V; Cetin I; Frusca T; Ghi T; Kaihura C; Di Pasquo E; Stampalija T; Belcaro C; Quadrifoglio M; Veneziano M; Mecacci F; Simeone S; Locatelli A; Consonni S; Chianchiano N; Labate F; Cromi A; Bertucci E; Facchinetti F; Fichera A; Granata D; D'Antonio F; Foti F; Avagliano L; Bulfamante GP; Calì G;
    Ultrasound Obstet Gynecol; 2022 Sep; 60(3):381-389. PubMed ID: 35247287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
    Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT
    Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver agreement in MRI assessment of severity of placenta accreta spectrum disorders.
    Finazzo F; D'antonio F; Masselli G; Forlani F; Palacios-Jaraquemada J; Minneci G; Gambarini S; Timor-Tritsch I; Prefumo F; Buca D; Liberati M; Khalil A; Cali G
    Ultrasound Obstet Gynecol; 2020 Apr; 55(4):467-473. PubMed ID: 31237043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Placental Vesicles Carry HLA-DR in Pre-Eclampsia: A New Potential Marker of the Syndrome.
    Tersigni C; Lucchetti D; Franco R; Colella F; Neri C; Crispino L; Sgambato A; Lanzone A; Scambia G; Vatish M; Di Simone N
    Front Immunol; 2021; 12():717879. PubMed ID: 34539654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders.
    Penzhoyan GA; Makukhina TB
    J Perinat Med; 2019 Dec; 48(1):21-26. PubMed ID: 31730533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder.
    Hussein AM; Elbarmelgy RA; Elbarmelgy RM; Thabet MM; Jauniaux E
    Ultrasound Obstet Gynecol; 2022 Apr; 59(4):474-482. PubMed ID: 34225385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syncytiotrophoblast-derived extracellular vesicles carry apolipoprotein-E and affect lipid synthesis of liver cells in vitro.
    Tersigni C; Furqan Bari M; Cai S; Zhang W; Kandzija N; Buchan A; Miranda F; Di Simone N; Redman CW; Bastie C; Vatish M
    J Cell Mol Med; 2022 Jan; 26(1):123-132. PubMed ID: 34894055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placenta accreta spectrum in major placenta previa diagnosed only by MRI: incidence, risk factors, and maternal morbidity.
    Shaamash AH; AlQasem MH; Al Ghamdi DS; Mahfouz AA; Eskandar MA
    Ann Saudi Med; 2023; 43(4):219-217. PubMed ID: 37554027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis.
    Jauniaux E; Bhide A
    Am J Obstet Gynecol; 2017 Jul; 217(1):27-36. PubMed ID: 28268196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of abnormal placentation on maternal serum fetal fraction of cell-free DNA.
    Rodriguez M; Smith EL; Silva LM; Gultekin-Elbir EE; Tetla R; Genc MR
    J Perinat Med; 2023 Jan; 51(1):97-101. PubMed ID: 36383690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of maternal serum VEGF, TNF-alpha, IL-4, and IL-10 levels in differentiating placenta accreta spectrum from isolated placenta previa.
    Farisoğullari N; Tanaçan A; Sakcak B; Denizli R; Baştemur AG; Başaran E; Kara Ö; Yazihan N; Şahin D
    Cytokine; 2024 Apr; 176():156513. PubMed ID: 38262117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal and fetal outcome in placenta accreta spectrum (PAS) associated with placenta previa: a retrospective analysis from a tertiary center.
    Varlas VN; Bors RG; Birsanu S; Maxim B; Clotea E; Mihailov M
    J Med Life; 2021; 14(3):367-375. PubMed ID: 34377203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
    Wehrum MJ; Buhimschi IA; Salafia C; Thung S; Bahtiyar MO; Werner EF; Campbell KH; Laky C; Sfakianaki AK; Zhao G; Funai EF; Buhimschi CS
    Am J Obstet Gynecol; 2011 May; 204(5):411.e1-411.e11. PubMed ID: 21316642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
    Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
    J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta.
    Oztas E; Ozler S; Ersoy AO; Ersoy E; Caglar AT; Uygur D; Yucel A; Ergin M; Danisman N
    Placenta; 2016 Mar; 39():1-6. PubMed ID: 26992667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antenatal diagnosis of placenta accreta spectrum (PAS) disorders.
    Yu FNY; Leung KY
    Best Pract Res Clin Obstet Gynaecol; 2021 Apr; 72():13-24. PubMed ID: 32747328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between a prenatal sonographic scoring system and a clinical grading at delivery for Placenta Accreta Spectrum disorders.
    Pekar-Zlotin M; Maymon R; Eliassi Revivo P; Ezratty J; Melcer Y; Kugler N; Jauniaux E
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):8810-8816. PubMed ID: 34818979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.